- Trial Phase
- Phase 3
- Time to Market
- Phase 3 trials are enrolling now; topline data expected in 2027. If successful, a 505(b)(2) NDA submission would follow, with potential FDA approval possibly in 2028-2029.
- Why 5/10
- The next hard catalyst is topline Phase 3 data readout from the two registrational trials (SGP-005 and SGP-006), expected in 2027 but without a specific date announced yet. Since the exact date is not yet scheduled within the next ~12 months and the company went public only in Feb 2026, the impactScore is capped at 5 despite this being the company's lead asset.
Watch for Phase 3 topline readout (expected in 2027, no precise date yet) as the defining binary catalyst. The FIH 4-year data (Oct 2026) de-risks Phase 3 replication risk somewhat, but Phase 3 results will determine whether the 505(b)(2) NDA submission proceeds. Also monitor FDA alignment updates and any accelerated enrollment announcements.
Price Chart
Executive Summary
SpyGlass Pharma (Nasdaq: SGP) is developing the BIM-IOL System (Bimatoprost Drug Pad-IOL System), a drug-eluting intraocular lens that combines cataract surgery with sustained-release glaucoma treatment. Phase 1/2 data showed 97% of patients off glaucoma drops at 12 months and sustained 37% IOP reduction at 4 years with no product-related adverse events. Two Phase 3 registrational trials are enrolling with topline readout expected in 2027. The company went public in Feb 2026, raising $172.5M, with $251M cash runway through 2028. With a strong-buy analyst consensus (mean PT $44, ~54% upside), massive Q2 2026 institutional accumulation, and recent vertical integration of IOL manufacturing via the AVS acquisition, the stock offers a high-risk/high-reward binary opportunity centered on Phase 3 success.
How It Works
Bimatoprost is a prostaglandin analog — a drug class that reduces pressure inside the eye by improving fluid drainage. The BIM-IOL System is a combination product: a standard intraocular lens (IOL) used to replace the cataract-clouded natural lens, coated with a drug pad that slowly releases bimatoprost over years. In a single cataract surgery, the patient gets both their vision restored and their glaucoma treated continuously, eliminating the need for daily eye drops.
Trial Status
Two identical Phase 3 registrational trials (SGP-005 and SGP-006) are enrolling patients, with first patients randomized in January 2026. The 78-mcg dose is being studied based on Phase 1/2 results. Positive 4-year interim data from the first-in-human trial (N=21 evaluable) was reported in October 2026, showing 37% mean IOP reduction and 86% of patients off all topical drops with no product-related adverse events.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 topline data readout expected in 2027 (no specific date announced)
- FDA alignment updates on 505(b)(2) NDA pathway
- Phase 3 enrollment completion announcements
- BIM-DRS (differentiated drug release system) first-in-human trial expected H2 2026
Source Filing
The SecBot filing or press-release report that triggered this drug report:
SpyGlass Pharma, Inc. 8-K SGP ·Originating report